ClinicalTrials.gg
Not yet recruitingNCT07507188INSTARUpdated Apr 2, 2026

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

A Phase 2 interventional study of Amivantamab SC + Lazertinib PO and Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV) in Non Small Cell Lung Cancer, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 14 under way, 3 of them phase 3. amivantamab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
8th of 15
80 · median 80
Started
2026
the only one that year
Phase 2
6 of 15
4 open now
Primary completion
2031-01
later than 13 of 13 live
Registered
15th of 15
by date
Lead sponsor
1 of 15
Yonsei University

Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 2, reaches primary completion later than 13 of the 13 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About amivantamab

amivantamab: first FDA approval 2021 (RYBREVANT), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

  • In this study, we hypothesized that immune engagement by amivantamab will enhance antitumor efficacy by modulating the immune microenvironment in combination with lazertinib in patients with untreated EGFR-mutant NSCLC or with chemotherapy (carboplatin plus pemetrexed) after progression with 3rd generation (3G) EGFR TKI.
  • The primary objective of this study is to examine the patients' tumors for immunomodulatory effects of amivantamab-based regimens.
  • In a phase 2, two cohort clinical trial, treatment naïve patients with EGFR-mutant NSCLC will be treated with amivantamab SC plus oral lazertinib (Cohort 1, n=30) or patients with EGFR-mutant NSCLC progressed on or after 3G EGFR TKI treated with amivantamab SC plus chemotherapy (Cohort 2, n=30).
03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 years and older
  2. Provision of prior to any study specific procedures
  3. or cytologically confirmed Locally advanced, Recurrent, or NSCLC, performed on a and able to do a paired biopsy during treatment (C3D1)
  4. Documented activating EGFR mutation (Exon 19 deletion or L858R)
  5. defined by (RECIST) 1.1 criteria
  6. (ECOG) Performance Status (PS) of 0-1
  7. Resolution of all acute toxic effects of prior chemotherapy, radiotherapy or surgical procedures to National Cancer Institute (NCI) (CTCAE) Version 5.0: ≤ grade 1
  8. Patient should meet following requirements.

    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x (ULN)
    • ≤ 1.5 x ULN, (Patients with documented Gilbert's syndrome and conjugated bilirubin within the normal range may be allowed into the study; in this event, it will be documented that the patient was eligible based on conjugated bilirubin levels)
    • Leukocytes ≥ 3.0 x 10\^3/μL
    • ≥ 9.0 g/dL, with no blood transfusions in the 28 days prior to study entry
    • ≥ 1.5 x 10\^3/μL
    • ≥ 75 x 10\^3/μL
    • Creatinine ≤ 1.5 x upper limit of normal (ULN) OR (details in Appendix 10. Cockcroft-Gault Formula for Estimated Creatinine Clearance) >50 mL/min for patients with creatinine levels >1.5 x upper limit above institutional normal
  9. Ability to swallow oral medications
  10. Male or female (according to their reproductive organs and functions assigned by chromosomal complement at birth).
  11. A female using oral contraceptivesmust use an additional barrier method (details in Appendix 5: Contraceptive Guidance). A female participant must be either of the following (as defined in Appendix 5: Contraceptive Guidance)

    1. Not of : premenarchal; (>45 years of age with amenorrhea for at least 12 months); permanently sterilized (eg, bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise, be incapable of pregnancy.
    2. Of childbearing potential and practicing at least 1 highly effective method(s) of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies, as described below:

      • Practicing true abstinence (when this is in line with the preferred and usual lifestyle of the participant), which is defined as refraining from heterosexual intercourse during the entire period of the study, and for 7 months after the last dose of the study treatment. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not considered an acceptable contraceptive method.
      • Have a sole partner who is vasectomized.
      • Practicing 2 methods of contraception, including one highly effective method (ie, established use of oral, intravaginal, transdermal, injected or implanted hormonal methods of contraception; placement of an intrauterine device [IUD] or intrauterine system [IUS], tubal ligation procedures as consistent with local regulations), AND, a second method, (eg, condom with spermicidal foam/gel/film/cream/suppository or occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository).
      • Participants must agree to continue contraception throughout the study and continuing through 7 months after the last dose of the study treatment.

    Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) the woman must begin a method of birth control, including 1 highly effective method, as described above.

  12. A female participant of childbearing potential must have a negative serum (b-human chorionic gonadotropin [b-hCG]) at screening (within 72 hours of the first dose of study treatment administration) and must agree to further serum or urine pregnancy tests during the study prior to Day 1 of each cycle and at End of Study.
  13. A female must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 7 months after the last dose of the study treatment. Female participants should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility.
  14. A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 6 months after the last dose of the study treatment.
  15. If the male participant's partner is a female of childbearing potential, the male participant must use condom with or without spermicide and the female partner of the male participant must also be practicing a highly effective method of contraception (see Appendix 5: Contraceptive Guidance). A male participant who is vasectomized must still use a condom (with or without spermicide), but the partner is not required to use contraception.
  16. A male participant must agree not to donate sperm for the purposes of reproduction during the study and for 6 months after the last dose of the study treatment (whichever comes last). Male participants should consider preservation of sperm prior to study treatment as anti-cancer treatments may impair fertility.
  17. A male participant must agree not to plan to father a child while enrolled in this study and for 7 months after the last dose of the study treatment (whichever comes last).

Exclusion criteria

Exclusion Criteria:

  1. or uncontrolled central nervous system (CNS)
  2. Symptomatic spinal cord compression that has not been treated definitively with surgery or radiation
  3. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease
  4. Patients who are known to be serologically positive for (HIV)
  5. Participant has concurrent or prior other than the disease under study. The following exceptions require consultation with the Principal Investigator:

    1. Non-muscle invasive bladder cancer (NMIBC) treated within the last 24 months that is considered completely cured.
    2. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.
    3. Non-invasive cervical cancer treated within the last 24 months that is considered completely cured.
    4. Localized prostate cancer (N0M0):

      • with a Gleason score of 6, treated within the last 24 months or untreated and under surveillance,
      • with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence,
      • or history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence.
    5. Breast cancer:

      - lobular carcinoma in situ or ductal carcinoma in situ that is considered completely cured.

    6. Participant has undergone curative therapy and is considered cured after 5 years with no evidence of disease recurrence since initiation of that therapy.
  6. Any of the following cardiac criteria:

    • Patient with any factors that increase the risk of prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum/plasma potassium \< LLN; Serum/plasma magnesium \< LLN; Serum/plasma calcium \< LLN) congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes. (details in Appendix 11: Medications With Potential for QT Interval Prolongation)
  7. Treatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megesterol acetate], or immunotherapy) ≤ 14 days prior to treatment with an drug
  8. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or known active infection (within 2 weeks prior to first day of study drug treament); screening for chronic conditions is not required
  9. Participant has at Screening:

    • Positive (hepatitis B virus [HBV]) surface antigen (HBsAg) Note: Participants with a prior history of HBV demonstrated by positive core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) an HBV DNA (viral load) below the lower limit of quantification, per local testing. Participants with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.
    • Positive (hepatitis C virus [HCV]) antibody (anti-HCV) Note: Participants with a prior history of HCV who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.
    • Other clinically active infectious liver disease
  10. Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:

    • Not receiving highly active antiretroviral therapy (ART)
    • Had a change in ART within 6 months of the start of screening
    • Receiving ART that may interfere with study treatment
    • \<350 at screening
    • AIDS-defining opportunistic infection within 6 months of start of screening
    • Not agreeing to start ART and be on ART>4 weeks plus having HIV viral load \<400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled).
  11. Treatment with an investigational drug within three half-lives of the compound or 3 months, whichever is greater.
  12. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of study drug.
  13. Active tuberculosis
  14. Females who are pregnant or breastfeeding
  15. Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications
  16. History of or intolerance to active or inactive of study drug or drugs with a similar chemical structure or class
  17. Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)
  18. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that interfere with the patient's safety, ability to provide , or ability to comply with the protocol.
  19. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  20. Participant has a history of cardiovascular disease including, but not limited to the following:

    • Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment, or any of the following within 24 weeks prior to enrollment: myocardial infarction, unstable angina, stroke, , coronary/peripheral artery bypass graft, or acute coronary syndrome (Note: clinically non-significant thrombosis, such as non-obstructive catheter-associated thrombus, or incidental or asymptomatic pulmonary embolism, is not exclusionary)
    • Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden).
    • Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines.
    • Uncontrolled hypokalemia or clinically significant cardiac arrythmia or electrophysiologic disease (eg, placement if implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate).
    • Uncontrolled (persistent) hypertension despite optimal treatment: systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg.
    • Congestive heart failure (CHF) defined as (NYHA) class III-IV (see Appendix 8: New York Heart Association Criteria) or hospitalization for CHF (any NYHA class) within 6 months of enrollment.
    • Pericarditis, pericardial effusion, or myocarditis that is clinically unstable. Pericardial effusion considered due to the disease under study is permitted if clinically stable at screening.
  21. Participant is currently receiving a medication or herbal supplement known to be a strong cytochrome P450 (CYP) 3A4/5 inducer and is not able to stop use for an appropriate prior to enrollment (details in Appendix 12: Prohibited or Restricted Medications and Therapies).
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    • No prior exposure to 1st, 2nd, or 3rd EGFR TKIs

    Drug: Amivantamab SC + Lazertinib PO

  • Experimental
    Cohort 2

    • Disease progression after prior treatment with 3rd generation (3G) EGFR TKI (including osimertinib, lazertinib)

    Drug: Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)

Interventions

  • DrugAmivantamab SC + Lazertinib PO

    • Amivantamab SC plus Lazertinib PO: 28-day Cycles * Amivantamab 1600/2240 mg SC QW up to C2D1 and Q2W thereafter; * Lazertinib 240 mg PO QD

  • DrugAmivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)

    Drug page: AmivantamabStudies of AmivantamabAmivantamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * Amivantamab SC plus Chemotherapy: 21-day Cycles 1-4 * Amivantamab 1600/2240 mg SC C1D1; 2400/3360 mg C1D8, C1D15, and Day 1 of Cycles 2, 3, 4 * Pemetrexced 500 mg/m2 IV Day 1 * Carboplatin AUC5 IV Day 1 * Amivantamab SC plus Chemotherapy: 21-day Cycles 5+ * Amivantamab 2400/3360 mg SC Day 1 * Pemetrexed 500 mg/m2 IV Day 1

06

What researchers measure

Primary outcomes

  1. • scRNA-seq and/or spatial RNA sequencing analysis. Multiplex IHC and/or FACS analysis.

    • Molecular candidates associated with the activity of amivantamab-based regimens identified by analyzing scRNA-seq and/or spatial RNA sequencing from pre-treatment tumor biopsy specimens and tumor tissue acquired at the time of C3D1. Multiplex IHC and/or FACS analysis performed either pre-treatment or post-treatment.

    Time frame: through study completion, an average of 5 year

Secondary outcomes

  1. Objective Response rate (ORR)

    Objective Response rate (ORR): the proportion of participants who achieve a CR or PR, based on RECIST v1.1.

    Time frame: through study completion, an average of 5 year

  2. Progression-free survival (PFS)

    Progression-free survival (PFS): the time from the first dose of study treatment until the date of objective disease progression or death, whichever comes first, based on RECIST v1.1.

    Time frame: through study completion, an average of 5 year

  3. Duration of response (DoR)

    Duration of response (DoR): the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR

    Time frame: through study completion, an average of 5 year

  4. circulating tumor DNA (ctDNA).

    To assess EGFR mutations, MET alterations, and mutations in other key oncogenes, samples for ctDNA analysis will be collected

    Time frame: through study completion, an average of 5 year

Other outcomes

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (TRAE, Clinical laboratory test, Vital signs, Physical Examination, Weight)

    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (TRAE, Clinical laboratory test, Vital signs, Physical Examination, Weight)

    Time frame: through study completion, an average of 5 year

  2. The biomarker and ctDNA samples.

    The biomarker and ctDNA samples may be used to explore the potential to predict clinical benefit, relapse, and/or identify mechanism of resistance to assigned treatment, and to enable the development of safer, more effective, and ultimately individualized therapies.

    Time frame: through study completion, an average of 5 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jan 2031, 57 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 57 months is close to that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Apr 2, 2026
StartEst.
Apr 6, 2026
Primary completionEst.
Jan 31, 2031
CompletionEst.
Jan 31, 2031
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507188
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Apr 6, 2026 (estimated)
Primary completion
Jan 31, 2031 (estimated)
Completion
Jan 31, 2031 (estimated)
Last update
Apr 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amivantamab

Start the discussion